Ownership history in GREAT POINT PARTNERS LLC Β· 7 quarters on record
This page tracks every 13F SEC filing in which GREAT POINT PARTNERS LLC reported a position in DIANTHUS THERAPEUTICS INC (DNTH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π GREAT POINT PARTNERS LLC outperformed the S&P 500 by +51.1% annually on this DNTH position. Timing score: 67% (2/3 decisions correct). Average cost basis: $31.82. Maximum drawdown during holding period: β33.7%.
π₯ Exceptional β beat the S&P 500 by 51.1% per year on this position.
5 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
2 of 3 add/trim decisions correct
Best entry: $25.88 (2024 Q2) Β· Worst: $41.21 (2025 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 2 trims. Bought during 0 of 2 down-price quarters. π More buys than sells across the holding period.
π GREAT POINT PARTNERS LLC has been actively increasing its DNTH allocation β a bullish signal from insiders.
Currently 4.68% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size